A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Trial Details

NCT ID

NCT05361174

Phase

PHASE1 / PHASE2

Sponsor

Iovance Biotherapeutics, Inc.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• IOV-4001

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• Miami, Florida, United States|25.77427,-80.19366
• Orlando, Florida, United States|28.53834,-81.37924
• Tampa, Florida, United States|27.94752,-82.45843
• Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

• Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC.
• Participants who have received the following previous therapy:
• Cohort 1 (Melanoma): Participants who have progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody and received BRAF/MEK inhib…
• Cohort 2 (NSCLC): Participants who should have received no more than 3 prior lines of therapy and:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.